“I would expect going forward with the new tax regs globally that we would be largely closer to the 15% level from a global tax perspective in the long-term.”

In context

“with Berenberg. Kerry Ann Holford: A couple of questions from me, please. Firstly, looking at ADCETRIS, TUKYSA, Q2 performance was a little weaker than anticipated. I understand these drugs are perhaps facing increased competitive pressures, but would be interested to your strategy for reinvigorating that growth of those Seagen assets ex Padcev? And then secondly, a question on the guidance, specifically tax. And apologies if I missed this earlier. But Dave, what has changed with regard to the tax outlook for this year? And how sustainable is this underlying 13% tax rate going forward? Albert Bourla: Dave, you want to start with that and then Aamir can. David M. Denton: Yes. Just on the tax side, there were some onetime discrete items that allowed us to improve our tax position this year. I would expect going forward with the new tax regs globally that we would be largely closer to the 15% level from a global tax perspective in the long-term. Albert Bourla: Kerry, thanks for the question. I think your question is largely around the Seagen portfolio and the products. So we feel very good about how we integrated those products. As an example, we were able to cross-train all of our field forces. And now we're seeing the benefit of that come through in commercial performance. So if I look at Q2 and the entirety of our Seagen commercial portfolio, we grew 15% year-over-year. And that was while managing some of the competitive headwinds that you alluded to on ADCETRIS, which we are starting to see now settle. In particular, we feel very good about the growth in Padcev. We have greater than 50% market share in the first line, and we see headroom to continue to expand that share, especially in the cisplatinum eligible population where”